Lessons from the pandemic: Responding to emerging zoonotic viral diseases — a Keystone Symposia report
- Creators
- Cable, Jennifer
-
Fauci, Anthony
- Dowling, William E.
-
Günther, Stephan
-
Bente, Dennis A.
-
Yadav, Pragya Dhruv
-
Madoff, Lawrence C.
-
Wang, Lin-Fa
-
Arora, Rahul K.
-
Van Kerkhove, Maria
-
Chu, May C.
-
Jaenisch, Thomas
-
Epstein, Jonathan H.
- Frost, Simon David William
-
Bausch, Daniel G.
-
Hensley, Lisa E.
-
Bergeron, Éric
-
Sitaras, Ioannis
-
Gunn, Michael D.
-
Geisbert, Thomas W.
-
Muñoz-Fontela, César
-
Krammer, Florian
-
de Wit, Emmie
-
Nordenfelt, Pontus
-
Saphire, Erica Ollmann
- Gilbert, Sarah C.
-
Corbett, Kizzmekia S.
- Branco, Luis M.
-
Baize, Sylvain
-
van Doremalen, Neeltje
-
Krieger, Marco A.
-
Costa Clemens, Sue Ann
- Hesselink, Renske
- Hartman, Dan
Abstract
The COVID‐19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10–13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium "Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases" to discuss the successes and challenges of the COVID‐19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID‐19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID‐19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements — notably, in low‐to‐middle income countries — must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens.
Additional Information
Funding Information: National Institute of Allergy and Infectious Diseases; Canadian Medical Association; Public Health Agency of Canada; Robert Koch Institute; German Federal Ministry of Health COVID-19 Research and Development; WHO Solidarity Response Fund R.K.A. and M.V.K. presented work funded by the WHO Solidarity Response Fund and the German Federal Ministry of Health COVID‐19 Research and Development. R.K.A. would also like to thank the following additional funders of SeroTracker's SARS‐CoV‐2 evidence synthesis efforts: the Public Health Agency of Canada through Canada's COVID‐19 Immunity Task Force, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund. M.V.K. is employed by the WHO; the authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policies, or views of WHO. E.d.W. and N.v.D. are supported by the Intramural Research Program of NIAID, NIH.Additional details
- PMCID
- PMC9538336
- Eprint ID
- 117477
- Resolver ID
- CaltechAUTHORS:20221017-15547800.42
- National Institute of Allergy and Infectious Diseases
- Canadian Medical Association
- Public Health Agency of Canada
- Created
-
2022-10-21Created from EPrint's datestamp field
- Updated
-
2023-01-25Created from EPrint's last_modified field
- Caltech groups
- COVID-19